Efficacy at a cost: camrelizumab and famitinib within the expanding landscape of combination therapies
Teresa Zumarraga-Lizundia, Arantzazu Barquin-Garcia, Ainhoa Madariaga · 2026
Read Efficacy at a cost: camrelizumab and famitinib within the expanding landscape of combination therapies by Teresa Zumarraga-Lizundia, Arantzazu Barquin-Garcia, Ainhoa Madariaga (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13345789.txt.
Description
Teresa Zumarraga-Lizundia, Arantzazu Barquin-Garcia, and Ainhoa Madariaga weigh a two-drug pairing for advanced cervical cancer in a 2026 commentary. Cervical cancer still ranks among the top killers of women worldwide, and once disease returns or spreads, about a third of patients worsen within six months of first-line chemo combinations.
The authors map second-line gains from immune drugs and antibody-drug conjugates, citing survival edges for cemiplimab and tisotumab vedotin over standard chemo, then place camrelizumab plus famitinib inside that crowded field. Response rates for plain chemo sit at just 5 to 10 percent, so any pairing must prove real added benefit against its side-effect cost. Careful patient selection will decide where the combo fits.
Catalog record
| CREATOR | Teresa Zumarraga-Lizundia, Arantzazu Barquin-Garcia, Ainhoa Madariaga |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12358 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |